Drugs / Neoantigen Polypeptide Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06195293 | Jun 2024 → Dec 2029 expected | cancer | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06341907 | Jan 2024 → Dec 2026 expected | malignant epithelial tumor of ovary | Second Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen Polypeptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06195293 ↗ |
| Modality | Vaccine | “polypeptide vaccine” NCT06195293 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06341907 ↗ |